{"id":"NCT03068455","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma","officialTitle":"A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-11","primaryCompletion":"2020-06-12","completion":"2021-02-02","firstPosted":"2017-03-01","resultsPosted":"2021-07-22","lastUpdate":"2021-09-20"},"enrollment":1844,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"nivolumab","otherNames":["Opdivo","BMS-936558"]},{"type":"BIOLOGICAL","name":"ipilimumab","otherNames":["Yervoy","BMS-734016"]}],"arms":[{"label":"nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"label":"nivolumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma","primaryOutcome":{"measure":"Recurrence-free Survival (RFS) - All Randomized Participants","timeFrame":"From randomization to Primary Completion Date (up to approximately 3 years)","effectByArm":[{"arm":"Arm A: Nivo + Ipi","deltaMin":null,"sd":null},{"arm":"Arm B: Nivo","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":124,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Greece","Israel","Italy","New Zealand","Poland","Romania","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["40645660","36162037","35512259"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":374,"n":916},"commonTop":["Fatigue","Diarrhoea","Pruritus","Rash","Headache"]}}